The global nuclear medicine market size is expected to reach USD 22.3 billion by 2030, registering a CAGR of 11.8% over the forecast period. The increasing prevalence of chronic diseases such as cancer & thyroid is anticipated to drive market growth. The impending approval of multiple radiopharmaceutical therapeutics during the forecast period will be a major driver for the market. For instance, in March 2022, Novartis AG received approval for Pluvicto (Lu 177) for the treatment of adult patients with prostate cancer. ![Global Nuclear Medicine Market]( "Global Nuclear Medicine Market")
According to the Pan American Health Organization (PAHO), in 2022, globally around 20 million new cases of cancer are estimated to be diagnosed, and around 10 million deaths occurred due to this disease. Factors like changing lifestyle, unhealthy diet, and less awareness about oral hygiene in low and middle-income countries is the most common cause of the prevalence of cancer.
Increasing adoption of nuclear medicine products in diagnosis and the approval of new generators to help increase the supply of radionuclides is expected to drive growth. For instance, in November 2021, EZAG received the Brazilian Health Authority Regulatory Agency’s (ANVISA) approval for GalliaPharm in Brazil. It is a gallium-68 generator used to extract the positron-emitting isotope of gallium from a source of decaying germanium-68 for making G68 dotatate injection. This is the first and only gallium generator approved for pharmaceutical use in Brazil. The approval of such products contributes to the market growth in developing markets.
In light of the COVID-19 pandemic, the market was moderately impacted. A survey was conducted for reactor-based medical isotopes by International Atomic Energy Agency (IAEA) during the second quarter of 2020 to assess the continuity of the supply chain during the COVID-19 crisis. It was revealed that major producers continued with production in line with IAEA safety standards, as their operations were categorized as essential by their respective governments.
This product will be delivered within 1-3 business days.
According to the Pan American Health Organization (PAHO), in 2022, globally around 20 million new cases of cancer are estimated to be diagnosed, and around 10 million deaths occurred due to this disease. Factors like changing lifestyle, unhealthy diet, and less awareness about oral hygiene in low and middle-income countries is the most common cause of the prevalence of cancer.
Increasing adoption of nuclear medicine products in diagnosis and the approval of new generators to help increase the supply of radionuclides is expected to drive growth. For instance, in November 2021, EZAG received the Brazilian Health Authority Regulatory Agency’s (ANVISA) approval for GalliaPharm in Brazil. It is a gallium-68 generator used to extract the positron-emitting isotope of gallium from a source of decaying germanium-68 for making G68 dotatate injection. This is the first and only gallium generator approved for pharmaceutical use in Brazil. The approval of such products contributes to the market growth in developing markets.
In light of the COVID-19 pandemic, the market was moderately impacted. A survey was conducted for reactor-based medical isotopes by International Atomic Energy Agency (IAEA) during the second quarter of 2020 to assess the continuity of the supply chain during the COVID-19 crisis. It was revealed that major producers continued with production in line with IAEA safety standards, as their operations were categorized as essential by their respective governments.
Nuclear Medicine Market Report Highlights
- By product type, the SPECT segment held the largest share of the diagnostics market due to low cost, high accuracy, and wide usage in different applications.
- The PET segment is expected to grow lucratively over the forecast period due to the approval & launch of new products such as PYLARIFY PET imaging agent for prostate cancer.
- By application, the oncology segment dominated the market in 2022 with a share of 41.99%.
- North America dominated the market with a share of 45.4% in 2022, owing to increased awareness about current treatment therapies, favorable reimbursement policies, and improved patient affordability.
- The Asia Pacific region is expected to be the fastest-growing region considerably in the future due to the rising prevalence of chronic diseases, rising geriatric population, and approval of new products during the forecast period.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Research Methodology
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 OBJECTIVE 1
1.10.2 OBJECTIVE 2
1.10.3 OBJECTIVE 3
1.10.4 OBJECTIVE 4
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 OBJECTIVE 1
1.10.2 OBJECTIVE 2
1.10.3 OBJECTIVE 3
1.10.4 OBJECTIVE 4
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 4 Industry Outlook
4.1 Market Variable Analysis
4.1.1 Rising incidence of cancer and cardiovascular diseases
4.1.2 Increasing application of radiopharmaceuticals/nuclear medicine
4.1.3 Growing demand for accurate diagnostic methods
4.2 Market Restraint Analysis
4.2.1 Stringent regulations pertaining to production, storage, & usage
4.2.2 High costs associated with diagnostics & therapeutic procedures
4.3 Swot Analysis; By Factor (Political & Legal, Economic And Technological)
4.4 Porter’s Five Forces Analysis
4.5 Value Chain Analysis
4.6 Production Process And Trends
4.6.1 Production Of Molybdenum-99 (Spect Radioisotopes)
4.6.2 Spect Radioisotopes Trends
4.6.3 Pet Radioisotopes Trends
4.6.3.1 Production Of Pet Radioisotopes
4.6.4 Therapeutic Radioisotopes Trends
4.6.4.1 Production Process And Trends
4.7 Nuclear Medicine Market - COVID-19 Impact
4.8 Pipeline Analysis
4.1.1 Rising incidence of cancer and cardiovascular diseases
4.1.2 Increasing application of radiopharmaceuticals/nuclear medicine
4.1.3 Growing demand for accurate diagnostic methods
4.2 Market Restraint Analysis
4.2.1 Stringent regulations pertaining to production, storage, & usage
4.2.2 High costs associated with diagnostics & therapeutic procedures
4.3 Swot Analysis; By Factor (Political & Legal, Economic And Technological)
4.4 Porter’s Five Forces Analysis
4.5 Value Chain Analysis
4.6 Production Process And Trends
4.6.1 Production Of Molybdenum-99 (Spect Radioisotopes)
4.6.2 Spect Radioisotopes Trends
4.6.3 Pet Radioisotopes Trends
4.6.3.1 Production Of Pet Radioisotopes
4.6.4 Therapeutic Radioisotopes Trends
4.6.4.1 Production Process And Trends
4.7 Nuclear Medicine Market - COVID-19 Impact
4.8 Pipeline Analysis
Chapter 5 Competitive Analysis
5.1 Vendor Landscape
5.1.1 List Of Key Distributors And Channel Partners
5.1.2 Key Company Market Share Analysis, 2022
5.2 Public Companies
5.2.1 Company Market Position Analysis
5.2.2 Competitive Dashboard Analysis
5.3 Private Companies
5.3.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
5.3.2 Regional Network Map
5.1.1 List Of Key Distributors And Channel Partners
5.1.2 Key Company Market Share Analysis, 2022
5.2 Public Companies
5.2.1 Company Market Position Analysis
5.2.2 Competitive Dashboard Analysis
5.3 Private Companies
5.3.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
5.3.2 Regional Network Map
Chapter 6 Product Business Analysis
6.1 Nuclear Medicine Market: Product Movement Analysis
6.2 Diagnostic Products
6.2.1 Diagnostic Products Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.2.1.1 SPECT
6.2.1.1.1 SPECT products market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.1.2 TC-99m
6.2.1.1.3 TC-99m market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.1.4 TL-201
6.2.1.1.5 TL-201 market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.1.6 GA-67
6.2.1.1.7 GA-67 market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.1.8 I-123
6.2.1.1.9 I-123 market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.1.10 Other SPECT products
6.2.1.1.11 Other SPECT products market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.2 PET
6.2.1.2.1 PET products market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.2.2 F-18
6.2.1.2.3 F-18 market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.2.4 SR-82/RB-82
6.2.1.2.5 SR-82/RB-82 market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.2.6 Other PET products
6.2.1.2.7 Other PET products market estimates and forecast, 2018 - 2030 (USD Million)
6.3 Therapeutic Products
6.3.1 Therapeutic Products market estimates and forecast, 2018 - 2030 (USD Million)
6.3.2 ALPHA EMITTERS
6.3.2.1 Alpha emitters market estimates and forecast, 2018 - 2030 (USD Million)
6.3.2.1.1 RA-223
6.3.2.1.1.1 RA-223 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3 BETA EMITTERS
6.3.3.1 Beta emitters market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3.2 I-131
6.3.3.2.1 I-131 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3.3 Y-90
6.3.3.3.1 Y-90 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3.4 SM-153
6.3.3.4.1 SM-153 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3.5 Re-186
6.3.3.5.1 Re-186 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3.6 Lu-177
6.3.3.6.1 Lu-177 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3.7 Other beta emitters
6.3.3.7.1 Other beta emitters market estimates and forecast, 2018 - 2030 (USD Million)
6.3.4 BRACHYTHERAPY
6.3.4.1 Brachytherapy market estimates and forecast, 2018 - 2030 (USD Million)
6.3.4.2 Cesium-131
6.3.4.2.1 Cesium-131 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.4.3 Iodine-125
6.3.4.3.1 Iodine-125 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.4.4 Palladium-103
6.3.4.4.1 Palladium-103 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.4.5 Iridium-192
6.3.4.5.1 Iridium-192 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.4.6 Other brachytherapy products
6.3.4.6.1 Other brachytherapy products market estimates and forecast, 2018 - 2030 (USD Million)
6.2 Diagnostic Products
6.2.1 Diagnostic Products Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.2.1.1 SPECT
6.2.1.1.1 SPECT products market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.1.2 TC-99m
6.2.1.1.3 TC-99m market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.1.4 TL-201
6.2.1.1.5 TL-201 market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.1.6 GA-67
6.2.1.1.7 GA-67 market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.1.8 I-123
6.2.1.1.9 I-123 market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.1.10 Other SPECT products
6.2.1.1.11 Other SPECT products market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.2 PET
6.2.1.2.1 PET products market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.2.2 F-18
6.2.1.2.3 F-18 market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.2.4 SR-82/RB-82
6.2.1.2.5 SR-82/RB-82 market estimates and forecast, 2018 - 2030 (USD Million)
6.2.1.2.6 Other PET products
6.2.1.2.7 Other PET products market estimates and forecast, 2018 - 2030 (USD Million)
6.3 Therapeutic Products
6.3.1 Therapeutic Products market estimates and forecast, 2018 - 2030 (USD Million)
6.3.2 ALPHA EMITTERS
6.3.2.1 Alpha emitters market estimates and forecast, 2018 - 2030 (USD Million)
6.3.2.1.1 RA-223
6.3.2.1.1.1 RA-223 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3 BETA EMITTERS
6.3.3.1 Beta emitters market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3.2 I-131
6.3.3.2.1 I-131 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3.3 Y-90
6.3.3.3.1 Y-90 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3.4 SM-153
6.3.3.4.1 SM-153 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3.5 Re-186
6.3.3.5.1 Re-186 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3.6 Lu-177
6.3.3.6.1 Lu-177 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3.7 Other beta emitters
6.3.3.7.1 Other beta emitters market estimates and forecast, 2018 - 2030 (USD Million)
6.3.4 BRACHYTHERAPY
6.3.4.1 Brachytherapy market estimates and forecast, 2018 - 2030 (USD Million)
6.3.4.2 Cesium-131
6.3.4.2.1 Cesium-131 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.4.3 Iodine-125
6.3.4.3.1 Iodine-125 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.4.4 Palladium-103
6.3.4.4.1 Palladium-103 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.4.5 Iridium-192
6.3.4.5.1 Iridium-192 market estimates and forecast, 2018 - 2030 (USD Million)
6.3.4.6 Other brachytherapy products
6.3.4.6.1 Other brachytherapy products market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 7 Application Business Analysis
7.1 Nuclear Medicine: Application Movement Analysis
7.1.1 Cardiology
7.1.1.1 Cardiology market estimates and forecast, 2018 - 2030 (USD Million)
7.1.2 Neurology
7.1.2.1 Neurology Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.1.3 Oncology
7.1.3.1 Oncology Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.1.4 Thyroid
7.1.4.1 Thyroid Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.1.5 Lymphoma
7.1.5.1 Lymphoma Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.1.6 Bone Metastasis
7.1.6.1 Bone Metastasis Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.1.7 Endocrine Tumor
7.1.7.1 Endocrine Tumor Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.1.8 Other Application
7.1.8.1 Other market estimates and forecast, 2018 - 2030 (USD Million)
7.1.1 Cardiology
7.1.1.1 Cardiology market estimates and forecast, 2018 - 2030 (USD Million)
7.1.2 Neurology
7.1.2.1 Neurology Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.1.3 Oncology
7.1.3.1 Oncology Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.1.4 Thyroid
7.1.4.1 Thyroid Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.1.5 Lymphoma
7.1.5.1 Lymphoma Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.1.6 Bone Metastasis
7.1.6.1 Bone Metastasis Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.1.7 Endocrine Tumor
7.1.7.1 Endocrine Tumor Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.1.8 Other Application
7.1.8.1 Other market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 8 End-use Business Analysis
8.1 Nuclear Medicine: End-use Movement Analysis
8.1.1 Hospitals & Clinics
8.1.1.1 Hospitals & Clinics Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.1.2 Diagnostics Centers
8.1.2.1 Diagnostic Centers Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.1.3 Others
8.1.3.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
8.1.1 Hospitals & Clinics
8.1.1.1 Hospitals & Clinics Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.1.2 Diagnostics Centers
8.1.2.1 Diagnostic Centers Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.1.3 Others
8.1.3.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 9 Regional Business Analysis
9.1 Nuclear Medicine Market: Regional Outlook
9.2 North America
9.2.1 North America Nuclear Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.2.2 U.S.
9.2.2.1 Key Country Dynamics
9.2.2.2 U.S. Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.2.2.3 Target Disease Prevalence
9.2.2.5 Competitive Scenario
9.2.2.6 Regulatory Framework
9.2.2.7 Reimbursement Scenario
9.2.3 Canada
9.2.3.1 Key Country Dynamics
9.2.3.2 Canada Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.2.3.3 Target Disease Prevalence
9.2.3.4 Competitive Scenario
9.2.3.5 Regulatory Framework
9.2.3.6 Reimbursement Scenario
9.3 Europe
9.3.1 Europe Nuclear Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.2 U.K.
9.3.2.1 Key Country Dynamics
9.3.2.2 U.K. Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.2.3 Target Disease Prevalence
9.3.2.4 Competitive Scenario
9.3.2.5 Regulatory Framework
9.3.2.6 Reimbursement Scenario
9.3.3 Germany
9.3.3.1 Key Country Dynamics
9.3.3.2 Germany Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.3.3 Target Disease Prevalence
9.3.3.4 Competitive Scenario
9.3.3.5 Regulatory Framework
9.3.3.6 Reimbursement Scenario
9.3.4 France
9.3.4.1 Key Country Dynamics
9.3.4.2 France Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.4.3 Target Disease Prevalence
9.3.4.4 Competitive Scenario
9.3.4.5 Regulatory Framework
9.3.4.6 Reimbursement Scenario
9.3.5 Italy
9.3.5.1 Key Country Dynamics
9.3.5.2 Italy Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.5.3 Target Disease Prevalence
9.3.5.4 Competitive Scenario
9.3.5.5 Regulatory Framework
9.3.5.6 Reimbursement Scenario
9.3.6 Spain
9.3.6.1 Key Country Dynamics
9.3.6.2 Spain Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.6.3 Target Disease Prevalence
9.3.6.4 Competitive Scenario
9.3.6.5 Regulatory Framework
9.3.6.6 Reimbursement Scenario
9.3.7 Denmark
9.3.9.1 Key Country Dynamics
9.3.9.2 Denmark Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.9.3 Target Disease Prevalence
9.3.9.4 Competitive Scenario
9.3.9.5 Regulatory Framework
9.3.9.6 Reimbursement Scenario
9.3.8 Sweden
9.3.8.1 Key Country Dynamics
9.3.8.2 Sweden Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.8.3 Target Disease Prevalence
9.3.8.4 Competitive Scenario
9.3.8.5 Regulatory Framework
9.3.8.6 Reimbursement Scenario
9.3.9 Norway
9.3.9.1 Key Country Dynamics
9.3.9.2 Norway Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.9.3 Target Disease Prevalence
9.3.9.4 Competitive Scenario
9.3.9.5 Regulatory Framework
9.3.9.6 Reimbursement Scenario
9.3.10 Russia
9.3.10.1 Key Country Dynamics
9.3.10.2 Russia Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.10.3 Target Disease Prevalence
9.3.10.4 Competitive Scenario
9.3.10.5 Regulatory Framework
9.3.10.6 Reimbursement Scenario
9.3.11 Netherlands
9.3.11.1 Key Country Dynamics
9.3.11.2 The Netherlands Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.11.3 Target Disease Prevalence
9.3.11.4 Competitive Scenario
9.3.11.5 Regulatory Framework
9.3.11.6 Reimbursement Scenario
9.4 Asia Pacific
9.4.1 Asia Pacific Nuclear Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.4.2 Japan
9.4.2.1 Key Country Dynamics
9.4.2.2 Japan Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.2.3 Target Disease Prevalence
9.4.2.4 Competitive Scenario
9.4.2.5 Regulatory Framework
9.4.2.6 Reimbursement Scenario
9.4.3 China
9.4.3.1 Key Country Dynamics
9.4.3.2 China Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.3.3 Target Disease Prevalence
9.4.3.4 Competitive Scenario
9.4.3.5 Regulatory Framework
9.4.3.6 Reimbursement Scenario
9.4.4 India
9.4.4.1 Key Country Dynamics
9.4.4.2 India Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.4.3 Target Disease Prevalence
9.4.4.4 Competitive Scenario
9.4.4.5 Regulatory Framework
9.4.4.6 Reimbursement Scenario
9.4.5 Australia
9.4.5.1 Key Country Dynamics
9.4.5.2 Australia Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.5.3 Target Disease Prevalence
9.4.5.4 Competitive Scenario
9.4.5.5 Regulatory Framework
9.4.5.6 Reimbursement Scenario
9.4.6 South Korea
9.4.6.1 Key Country Dynamics
9.4.6.2 South Korea Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.6.3 Target Disease Prevalence
9.4.6.4 Competitive Scenario
9.4.6.5 Regulatory Framework
9.4.6.6 Reimbursement Scenario
9.4.7 Thailand
9.4.7.1 Key Country Dynamics
9.4.7.2 Thailand Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.7.3 Target Disease Prevalence
9.4.7.4 Competitive Scenario
9.4.7.5 Regulatory Framework
9.4.7.6 Reimbursement Scenario
9.4.8 Philippines
9.4.8.1 Key Country Dynamics
9.4.8.2 Philippines Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.8.3 Target Disease Prevalence
9.4.8.4 Competitive Scenario
9.4.8.5 Regulatory Framework
9.4.8.6 Reimbursement Scenario
9.4.9 Singapore
9.4.9.1 Key Country Dynamics
9.4.9.2 New Zealand Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.9.3 Target Disease Prevalence
9.4.9.4 Competitive Scenario
9.4.9.5 Regulatory Framework
9.4.9.6 Reimbursement Scenario
9.4.10 Malaysia
9.4.10.1 Key Country Dynamics
9.4.10.2 Philippines Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.10.3 Target Disease Prevalence
9.4.10.4 Competitive Scenario
9.4.10.5 Regulatory Framework
9.4.10.6 Reimbursement Scenario
9.4.11 New Zealand
9.4.11.1 Key Country Dynamics
9.4.11.2 Philippines Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.11.3 Target Disease Prevalence
9.4.11.4 Competitive Scenario
9.4.11.5 Regulatory Framework
9.4.11.6 Reimbursement Scenario
9.5 Latin America
9.5.1 Latin America Nuclear Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.5.2 Brazil
9.5.2.1 Key Country Dynamics
9.5.2.2 Brazil Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.5.2.3 Target Disease Prevalence
9.5.2.4 Competitive Scenario
9.5.2.5 Regulatory Framework
9.5.2.6 Reimbursement Scenario
9.5.3 Mexico
9.5.3.1 Key Country Dynamics
9.5.3.2 Mexico Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.5.3.3 Target Disease Prevalence
9.5.3.4 Competitive Scenario
9.5.3.5 Regulatory Framework
9.5.3.6 Reimbursement Scenario
9.5.4 Argentina
9.5.4.1 Key Country Dynamics
9.5.4.2 Argentina Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.5.4.3 Target Disease Prevalence
9.5.4.4 Competitive Scenario
9.5.4.5 Regulatory Framework
9.5.4.6 Reimbursement Scenario
9.6 Middle East and Africa
9.6.1 Middle East and Africa Nuclear Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.6.1.1 Target Disease Prevalence
9.6.1.2 Competitive Scenario
9.6.1.3 Regulatory Framework
9.6.1.4 Reimbursement Scenario
9.6.2 South Africa
9.6.2.1 Key Country Dynamics
9.6.2.2 South Africa Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.6.2.3 Target Disease Prevalence
9.6.2.4 Competitive Scenario
9.6.2.5 Regulatory Framework
9.6.2.6 Reimbursement Scenario
9.6.3 Saudi Arabia
9.6.3.1 Key Country Dynamics
9.6.3.2 Saudi Arabia Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.6.3.3 Target Disease Prevalence
9.6.3.4 Competitive Scenario
9.6.3.5 Regulatory Framework
9.6.3.6 Reimbursement Scenario
9.6.4 UAE
9.6.4.1 Key Country Dynamics
9.6.4.2 UAE Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.6.4.3 Target Disease Prevalence
9.6.4.4 Competitive Scenario
9.6.4.5 Regulatory Framework
9.6.4.6 Reimbursement Scenario
9.6.5 KUWAIT
9.6.5.1 Key Country Dynamics
9.6.5.2 Kuwait Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.6.5.3 Target Disease Prevalence
9.6.5.4 Competitive Scenario
9.6.5.5 Regulatory Framework
9.6.5.6 Reimbursement Scenario
9.4.6 Israel
9.4.6.1 Key Country Dynamics
9.4.6.2 Israel Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.6.3 Target Disease Prevalence
9.4.6.4 Competitive Scenario
9.4.6.5 Regulatory Framework
9.4.6.6 Reimbursement Scenario
9.4.7 Turkey
9.4.7.1 Key Country Dynamics
9.4.7.2 Turkey Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.7.3 Target Disease Prevalence
9.4.7.4 Competitive Scenario
9.4.7.5 Regulatory Framework
9.4.7.6 Reimbursement Scenario
9.2 North America
9.2.1 North America Nuclear Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.2.2 U.S.
9.2.2.1 Key Country Dynamics
9.2.2.2 U.S. Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.2.2.3 Target Disease Prevalence
9.2.2.5 Competitive Scenario
9.2.2.6 Regulatory Framework
9.2.2.7 Reimbursement Scenario
9.2.3 Canada
9.2.3.1 Key Country Dynamics
9.2.3.2 Canada Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.2.3.3 Target Disease Prevalence
9.2.3.4 Competitive Scenario
9.2.3.5 Regulatory Framework
9.2.3.6 Reimbursement Scenario
9.3 Europe
9.3.1 Europe Nuclear Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.2 U.K.
9.3.2.1 Key Country Dynamics
9.3.2.2 U.K. Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.2.3 Target Disease Prevalence
9.3.2.4 Competitive Scenario
9.3.2.5 Regulatory Framework
9.3.2.6 Reimbursement Scenario
9.3.3 Germany
9.3.3.1 Key Country Dynamics
9.3.3.2 Germany Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.3.3 Target Disease Prevalence
9.3.3.4 Competitive Scenario
9.3.3.5 Regulatory Framework
9.3.3.6 Reimbursement Scenario
9.3.4 France
9.3.4.1 Key Country Dynamics
9.3.4.2 France Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.4.3 Target Disease Prevalence
9.3.4.4 Competitive Scenario
9.3.4.5 Regulatory Framework
9.3.4.6 Reimbursement Scenario
9.3.5 Italy
9.3.5.1 Key Country Dynamics
9.3.5.2 Italy Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.5.3 Target Disease Prevalence
9.3.5.4 Competitive Scenario
9.3.5.5 Regulatory Framework
9.3.5.6 Reimbursement Scenario
9.3.6 Spain
9.3.6.1 Key Country Dynamics
9.3.6.2 Spain Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.6.3 Target Disease Prevalence
9.3.6.4 Competitive Scenario
9.3.6.5 Regulatory Framework
9.3.6.6 Reimbursement Scenario
9.3.7 Denmark
9.3.9.1 Key Country Dynamics
9.3.9.2 Denmark Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.9.3 Target Disease Prevalence
9.3.9.4 Competitive Scenario
9.3.9.5 Regulatory Framework
9.3.9.6 Reimbursement Scenario
9.3.8 Sweden
9.3.8.1 Key Country Dynamics
9.3.8.2 Sweden Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.8.3 Target Disease Prevalence
9.3.8.4 Competitive Scenario
9.3.8.5 Regulatory Framework
9.3.8.6 Reimbursement Scenario
9.3.9 Norway
9.3.9.1 Key Country Dynamics
9.3.9.2 Norway Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.9.3 Target Disease Prevalence
9.3.9.4 Competitive Scenario
9.3.9.5 Regulatory Framework
9.3.9.6 Reimbursement Scenario
9.3.10 Russia
9.3.10.1 Key Country Dynamics
9.3.10.2 Russia Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.10.3 Target Disease Prevalence
9.3.10.4 Competitive Scenario
9.3.10.5 Regulatory Framework
9.3.10.6 Reimbursement Scenario
9.3.11 Netherlands
9.3.11.1 Key Country Dynamics
9.3.11.2 The Netherlands Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.11.3 Target Disease Prevalence
9.3.11.4 Competitive Scenario
9.3.11.5 Regulatory Framework
9.3.11.6 Reimbursement Scenario
9.4 Asia Pacific
9.4.1 Asia Pacific Nuclear Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.4.2 Japan
9.4.2.1 Key Country Dynamics
9.4.2.2 Japan Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.2.3 Target Disease Prevalence
9.4.2.4 Competitive Scenario
9.4.2.5 Regulatory Framework
9.4.2.6 Reimbursement Scenario
9.4.3 China
9.4.3.1 Key Country Dynamics
9.4.3.2 China Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.3.3 Target Disease Prevalence
9.4.3.4 Competitive Scenario
9.4.3.5 Regulatory Framework
9.4.3.6 Reimbursement Scenario
9.4.4 India
9.4.4.1 Key Country Dynamics
9.4.4.2 India Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.4.3 Target Disease Prevalence
9.4.4.4 Competitive Scenario
9.4.4.5 Regulatory Framework
9.4.4.6 Reimbursement Scenario
9.4.5 Australia
9.4.5.1 Key Country Dynamics
9.4.5.2 Australia Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.5.3 Target Disease Prevalence
9.4.5.4 Competitive Scenario
9.4.5.5 Regulatory Framework
9.4.5.6 Reimbursement Scenario
9.4.6 South Korea
9.4.6.1 Key Country Dynamics
9.4.6.2 South Korea Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.6.3 Target Disease Prevalence
9.4.6.4 Competitive Scenario
9.4.6.5 Regulatory Framework
9.4.6.6 Reimbursement Scenario
9.4.7 Thailand
9.4.7.1 Key Country Dynamics
9.4.7.2 Thailand Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.7.3 Target Disease Prevalence
9.4.7.4 Competitive Scenario
9.4.7.5 Regulatory Framework
9.4.7.6 Reimbursement Scenario
9.4.8 Philippines
9.4.8.1 Key Country Dynamics
9.4.8.2 Philippines Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.8.3 Target Disease Prevalence
9.4.8.4 Competitive Scenario
9.4.8.5 Regulatory Framework
9.4.8.6 Reimbursement Scenario
9.4.9 Singapore
9.4.9.1 Key Country Dynamics
9.4.9.2 New Zealand Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.9.3 Target Disease Prevalence
9.4.9.4 Competitive Scenario
9.4.9.5 Regulatory Framework
9.4.9.6 Reimbursement Scenario
9.4.10 Malaysia
9.4.10.1 Key Country Dynamics
9.4.10.2 Philippines Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.10.3 Target Disease Prevalence
9.4.10.4 Competitive Scenario
9.4.10.5 Regulatory Framework
9.4.10.6 Reimbursement Scenario
9.4.11 New Zealand
9.4.11.1 Key Country Dynamics
9.4.11.2 Philippines Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.11.3 Target Disease Prevalence
9.4.11.4 Competitive Scenario
9.4.11.5 Regulatory Framework
9.4.11.6 Reimbursement Scenario
9.5 Latin America
9.5.1 Latin America Nuclear Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.5.2 Brazil
9.5.2.1 Key Country Dynamics
9.5.2.2 Brazil Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.5.2.3 Target Disease Prevalence
9.5.2.4 Competitive Scenario
9.5.2.5 Regulatory Framework
9.5.2.6 Reimbursement Scenario
9.5.3 Mexico
9.5.3.1 Key Country Dynamics
9.5.3.2 Mexico Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.5.3.3 Target Disease Prevalence
9.5.3.4 Competitive Scenario
9.5.3.5 Regulatory Framework
9.5.3.6 Reimbursement Scenario
9.5.4 Argentina
9.5.4.1 Key Country Dynamics
9.5.4.2 Argentina Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.5.4.3 Target Disease Prevalence
9.5.4.4 Competitive Scenario
9.5.4.5 Regulatory Framework
9.5.4.6 Reimbursement Scenario
9.6 Middle East and Africa
9.6.1 Middle East and Africa Nuclear Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.6.1.1 Target Disease Prevalence
9.6.1.2 Competitive Scenario
9.6.1.3 Regulatory Framework
9.6.1.4 Reimbursement Scenario
9.6.2 South Africa
9.6.2.1 Key Country Dynamics
9.6.2.2 South Africa Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.6.2.3 Target Disease Prevalence
9.6.2.4 Competitive Scenario
9.6.2.5 Regulatory Framework
9.6.2.6 Reimbursement Scenario
9.6.3 Saudi Arabia
9.6.3.1 Key Country Dynamics
9.6.3.2 Saudi Arabia Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.6.3.3 Target Disease Prevalence
9.6.3.4 Competitive Scenario
9.6.3.5 Regulatory Framework
9.6.3.6 Reimbursement Scenario
9.6.4 UAE
9.6.4.1 Key Country Dynamics
9.6.4.2 UAE Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.6.4.3 Target Disease Prevalence
9.6.4.4 Competitive Scenario
9.6.4.5 Regulatory Framework
9.6.4.6 Reimbursement Scenario
9.6.5 KUWAIT
9.6.5.1 Key Country Dynamics
9.6.5.2 Kuwait Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.6.5.3 Target Disease Prevalence
9.6.5.4 Competitive Scenario
9.6.5.5 Regulatory Framework
9.6.5.6 Reimbursement Scenario
9.4.6 Israel
9.4.6.1 Key Country Dynamics
9.4.6.2 Israel Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.6.3 Target Disease Prevalence
9.4.6.4 Competitive Scenario
9.4.6.5 Regulatory Framework
9.4.6.6 Reimbursement Scenario
9.4.7 Turkey
9.4.7.1 Key Country Dynamics
9.4.7.2 Turkey Nuclear Medicine Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.7.3 Target Disease Prevalence
9.4.7.4 Competitive Scenario
9.4.7.5 Regulatory Framework
9.4.7.6 Reimbursement Scenario
Chapter 10 COMPANY PROFILES
10.1 Company Categorization
10.2 Strategy Mapping
10.2.1 New Product Launch
10.2.2 Partnerships
10.2.3 Acquisition
10.2.4 Collaboration
10.2.5 Funding
10.3 Key Company Market Share Analysis, 2022
10.4 Company Profiles
10.4.1 ECKERT & ZIEGLER
10.4.1.1 Company Overview
10.4.1.2 Financial Performance
10.4.1.3 Product Benchmarking
10.4.1.4 Strategic Initiatives
10.4.2 MALLINCKRODT
10.4.2.1 Company Overview
10.4.2.2 Financial Performance
10.4.2.3 Product Benchmarking
10.4.2.4 Strategic Initiatives
10.4.3 CURIUM PHARMA
10.4.3.1 Company Overview
10.4.3.2 Financial Performance
10.4.3.3 Product Benchmarking
10.4.3.4 Strategic Initiatives
10.4.4 GENERAL ELECTRIC
10.4.4.1 Company Overview
10.4.4.2 Financial Performance
10.4.4.3 Product Benchmarking
10.4.4.4 Strategic Initiatives
10.4.5 JUBILANT LIFE SCIENCES LTD.
10.4.5.1 Company Overview
10.4.5.2 Financial Performance
10.4.5.3 Product Benchmarking
10.4.5.4 Strategic Initiatives
10.4.6 BRACCO IMAGING S.P.A.
10.4.6.1 Company Overview
10.4.6.2 Financial Performance
10.4.6.3 Product Benchmarking
10.4.6.4 Strategic Initiatives
10.4.7 NORDION (CANADA), INC.
10.4.7.1 Company Overview
10.4.7.2 Financial Performance
10.4.7.3 Product Benchmarking
10.4.7.4 Strategic Initiatives
10.4.8 THE INSTITUTE FOR RADIOELEMENTS (IRE - IRE ELIT - BE)
10.4.8.1 Company Overview
10.4.8.2 Financial Performance
10.4.8.3 Product Benchmarking
10.4.8.4 Strategic Initiatives
10.4.9 AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANIZATION (ANSTO)
10.4.9.1 Company Overview
10.4.9.2 Financial Performance
10.4.9.3 Product Benchmarking
10.4.9.4 Strategic Initiatives
10.4.10 NTP RADIOISOTOPES SOC LTD.
10.4.10.1 Company Overview
10.4.10.2 Financial Performance
10.4.10.3 Product Benchmarking
10.4.10.4 Strategic Initiatives
10.4.11 ECZACIBASI-MONROL
10.4.11.1 Company Overview
10.4.11.2 Financial Performance
10.4.11.3 Product Benchmarking
10.4.11.4 Strategic Initiatives
10.4.12 LANTHEUS MEDICAL IMAGING, INC.
10.4.12.1 Company Overview
10.4.12.2 Financial Performance
10.4.12.3 Product Benchmarking
10.4.12.4 Strategic Initiatives
10.4.13 CARDINAL HEALTH
10.4.13.1 Company Overview
10.4.13.2 Financial Performance
10.4.13.3 Product Benchmarking
10.4.13.4 Strategic Initiatives
10.4.14 NOVARTIS AG
10.4.14.1 Company Overview
10.4.14.2 Financial Performance
10.4.14.3 Product Benchmarking
10.4.14.4 Strategic Initiatives
10.4.15 BAYER AG
10.4.15.1 Company Overview
10.4.15.2 Financial Performance
10.4.15.3 Product Benchmarking
10.4.15.4 Strategic Initiatives
10.4.16 POINT BIOPHARMA GLOBAL INC.
10.4.16.1 Company Overview
10.4.16.2 Financial Performance
10.4.16.3 Product Benchmarking
10.4.16.4 Strategic Initiatives
10.4.17 TELIX PHARMACEUTICALS
10.4.17.1 Company Overview
10.4.17.2 Financial Performance
10.4.17.3 Product Benchmarking
10.4.17.4 Strategic Initiatives
10.4.18 ACTINIUM PHARMACEUTICALS, INC
10.4.18.1 Company Overview
10.4.18.2 Financial Performance
10.4.18.3 Product Benchmarking
10.4.18.4 Strategic Initiatives
10.4.19 IBA GROUP
10.4.19.1 Company Overview
10.4.19.2 Financial Performance
10.4.19.3 Product Benchmarking
10.4.19.4 Strategic Initiatives
10.4.20 SIRTEX MEDICAL
10.4.20.1 Company Overview
10.4.20.2 Financial Performance
10.4.20.3 Product Benchmarking
10.4.20.4 Strategic Initiatives
10.2 Strategy Mapping
10.2.1 New Product Launch
10.2.2 Partnerships
10.2.3 Acquisition
10.2.4 Collaboration
10.2.5 Funding
10.3 Key Company Market Share Analysis, 2022
10.4 Company Profiles
10.4.1 ECKERT & ZIEGLER
10.4.1.1 Company Overview
10.4.1.2 Financial Performance
10.4.1.3 Product Benchmarking
10.4.1.4 Strategic Initiatives
10.4.2 MALLINCKRODT
10.4.2.1 Company Overview
10.4.2.2 Financial Performance
10.4.2.3 Product Benchmarking
10.4.2.4 Strategic Initiatives
10.4.3 CURIUM PHARMA
10.4.3.1 Company Overview
10.4.3.2 Financial Performance
10.4.3.3 Product Benchmarking
10.4.3.4 Strategic Initiatives
10.4.4 GENERAL ELECTRIC
10.4.4.1 Company Overview
10.4.4.2 Financial Performance
10.4.4.3 Product Benchmarking
10.4.4.4 Strategic Initiatives
10.4.5 JUBILANT LIFE SCIENCES LTD.
10.4.5.1 Company Overview
10.4.5.2 Financial Performance
10.4.5.3 Product Benchmarking
10.4.5.4 Strategic Initiatives
10.4.6 BRACCO IMAGING S.P.A.
10.4.6.1 Company Overview
10.4.6.2 Financial Performance
10.4.6.3 Product Benchmarking
10.4.6.4 Strategic Initiatives
10.4.7 NORDION (CANADA), INC.
10.4.7.1 Company Overview
10.4.7.2 Financial Performance
10.4.7.3 Product Benchmarking
10.4.7.4 Strategic Initiatives
10.4.8 THE INSTITUTE FOR RADIOELEMENTS (IRE - IRE ELIT - BE)
10.4.8.1 Company Overview
10.4.8.2 Financial Performance
10.4.8.3 Product Benchmarking
10.4.8.4 Strategic Initiatives
10.4.9 AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANIZATION (ANSTO)
10.4.9.1 Company Overview
10.4.9.2 Financial Performance
10.4.9.3 Product Benchmarking
10.4.9.4 Strategic Initiatives
10.4.10 NTP RADIOISOTOPES SOC LTD.
10.4.10.1 Company Overview
10.4.10.2 Financial Performance
10.4.10.3 Product Benchmarking
10.4.10.4 Strategic Initiatives
10.4.11 ECZACIBASI-MONROL
10.4.11.1 Company Overview
10.4.11.2 Financial Performance
10.4.11.3 Product Benchmarking
10.4.11.4 Strategic Initiatives
10.4.12 LANTHEUS MEDICAL IMAGING, INC.
10.4.12.1 Company Overview
10.4.12.2 Financial Performance
10.4.12.3 Product Benchmarking
10.4.12.4 Strategic Initiatives
10.4.13 CARDINAL HEALTH
10.4.13.1 Company Overview
10.4.13.2 Financial Performance
10.4.13.3 Product Benchmarking
10.4.13.4 Strategic Initiatives
10.4.14 NOVARTIS AG
10.4.14.1 Company Overview
10.4.14.2 Financial Performance
10.4.14.3 Product Benchmarking
10.4.14.4 Strategic Initiatives
10.4.15 BAYER AG
10.4.15.1 Company Overview
10.4.15.2 Financial Performance
10.4.15.3 Product Benchmarking
10.4.15.4 Strategic Initiatives
10.4.16 POINT BIOPHARMA GLOBAL INC.
10.4.16.1 Company Overview
10.4.16.2 Financial Performance
10.4.16.3 Product Benchmarking
10.4.16.4 Strategic Initiatives
10.4.17 TELIX PHARMACEUTICALS
10.4.17.1 Company Overview
10.4.17.2 Financial Performance
10.4.17.3 Product Benchmarking
10.4.17.4 Strategic Initiatives
10.4.18 ACTINIUM PHARMACEUTICALS, INC
10.4.18.1 Company Overview
10.4.18.2 Financial Performance
10.4.18.3 Product Benchmarking
10.4.18.4 Strategic Initiatives
10.4.19 IBA GROUP
10.4.19.1 Company Overview
10.4.19.2 Financial Performance
10.4.19.3 Product Benchmarking
10.4.19.4 Strategic Initiatives
10.4.20 SIRTEX MEDICAL
10.4.20.1 Company Overview
10.4.20.2 Financial Performance
10.4.20.3 Product Benchmarking
10.4.20.4 Strategic Initiatives
List of Tables
Table 1 Global Nuclear Medicine Market, By Region, 2018 - 2030 (USD Million)
Table 2 Global Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 3 Global Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 4 Global Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 5 North America Nuclear Medicine Market, By Region, 2018 - 2030 (USD Million)
Table 6 North America Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 7 North America Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 8 North America Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 9 U.S. Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 10 U.S. Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 11 U.S. Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 12 Canada Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 13 Canada Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 14 Canada Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 15 Europe Nuclear Medicine Market, By Region, 2018 - 2030 (USD Million)
Table 16 Europe Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 17 Europe Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 18 Europe Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 19 UK Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 20 UK Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 21 UK Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 22 Germany Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 23 Germany Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 24 Germany Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 25 France Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 26 France Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 27 France Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 28 Italy Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 29 Italy Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 30 Italy Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 31 Spain Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 32 Spain Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 33 Spain Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 34 Russia Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 35 Russia Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 36 Russia Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 37 Netherlands Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 38 Netherlands Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 39 Netherlands Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 40 Denmark Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 41 Denmark Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 42 Denmark Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 43 Sweden Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 44 Sweden Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 45 Sweden Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 46 Norway Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 47 Norway Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 48 Norway Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 49 Asia Pacific Nuclear Medicine Market, By Region, 2018 - 2030 (USD Million)
Table 50 Asia Pacific Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 51 Asia Pacific Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 52 Asia Pacific Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 53 Japan Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 54 Japan Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 55 Japan Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 56 China Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 57 China Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 58 China Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 59 India Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 60 India Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 61 India Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 62 Australia Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 63 Australia Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 64 Australia Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 65 Singapore Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 66 Singapore Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 67 Singapore Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 68 South Korea Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 69 South Korea Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 70 South Korea Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 71 Thailand Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 72 Thailand Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 73 Thailand Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 74 Philippines Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 75 Philippines Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 76 Philippines Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 77 New Zealand Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 78 New Zealand Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 79 New Zealand Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 80 Malaysia Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 81 Malaysia Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 82 Malaysia Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 83 Latin America Nuclear Medicine Market, By Region, 2018 - 2030 (USD Million)
Table 84 Latin America Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 85 Latin America Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 86 Latin America Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 87 Brazil Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 88 Brazil Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 89 Brazil Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 90 Mexico Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 91 Mexico Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 92 Mexico Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 93 Argentina Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 94 Argentina Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 95 Argentina Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 96 Middle East & Africa Nuclear Medicine Market, By Region, 2018 - 2030 (USD Million)
Table 97 Middle East & Africa Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 98 Middle East & Africa Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 99 Middle East & Africa Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 100 South Africa Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 101 South Africa Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 102 South Africa Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 103 Saudi Arabia Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 104 Saudi Arabia Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 105 Saudi Arabia Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 106 UAE Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 107 UAE Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 108 UAE Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 109 Turkey Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 110 Turkey Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 111 Turkey Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 112 Israel Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 113 Israel Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 114 Israel Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 115 Kuwait Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 116 Kuwait Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 117 Kuwait Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 2 Global Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 3 Global Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 4 Global Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 5 North America Nuclear Medicine Market, By Region, 2018 - 2030 (USD Million)
Table 6 North America Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 7 North America Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 8 North America Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 9 U.S. Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 10 U.S. Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 11 U.S. Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 12 Canada Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 13 Canada Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 14 Canada Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 15 Europe Nuclear Medicine Market, By Region, 2018 - 2030 (USD Million)
Table 16 Europe Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 17 Europe Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 18 Europe Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 19 UK Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 20 UK Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 21 UK Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 22 Germany Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 23 Germany Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 24 Germany Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 25 France Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 26 France Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 27 France Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 28 Italy Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 29 Italy Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 30 Italy Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 31 Spain Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 32 Spain Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 33 Spain Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 34 Russia Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 35 Russia Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 36 Russia Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 37 Netherlands Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 38 Netherlands Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 39 Netherlands Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 40 Denmark Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 41 Denmark Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 42 Denmark Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 43 Sweden Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 44 Sweden Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 45 Sweden Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 46 Norway Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 47 Norway Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 48 Norway Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 49 Asia Pacific Nuclear Medicine Market, By Region, 2018 - 2030 (USD Million)
Table 50 Asia Pacific Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 51 Asia Pacific Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 52 Asia Pacific Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 53 Japan Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 54 Japan Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 55 Japan Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 56 China Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 57 China Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 58 China Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 59 India Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 60 India Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 61 India Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 62 Australia Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 63 Australia Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 64 Australia Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 65 Singapore Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 66 Singapore Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 67 Singapore Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 68 South Korea Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 69 South Korea Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 70 South Korea Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 71 Thailand Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 72 Thailand Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 73 Thailand Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 74 Philippines Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 75 Philippines Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 76 Philippines Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 77 New Zealand Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 78 New Zealand Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 79 New Zealand Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 80 Malaysia Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 81 Malaysia Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 82 Malaysia Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 83 Latin America Nuclear Medicine Market, By Region, 2018 - 2030 (USD Million)
Table 84 Latin America Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 85 Latin America Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 86 Latin America Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 87 Brazil Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 88 Brazil Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 89 Brazil Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 90 Mexico Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 91 Mexico Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 92 Mexico Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 93 Argentina Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 94 Argentina Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 95 Argentina Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 96 Middle East & Africa Nuclear Medicine Market, By Region, 2018 - 2030 (USD Million)
Table 97 Middle East & Africa Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 98 Middle East & Africa Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 99 Middle East & Africa Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 100 South Africa Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 101 South Africa Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 102 South Africa Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 103 Saudi Arabia Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 104 Saudi Arabia Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 105 Saudi Arabia Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 106 UAE Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 107 UAE Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 108 UAE Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 109 Turkey Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 110 Turkey Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 111 Turkey Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 112 Israel Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 113 Israel Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 114 Israel Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
Table 115 Kuwait Nuclear Medicine Market, By Product, 2018 - 2030 (USD Million)
Table 116 Kuwait Nuclear Medicine Market, By Application, 2018 - 2030 (USD Million)
Table 117 Kuwait Nuclear Medicine Market, By End-use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Nuclear medicine market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Nuclear Medicine market snapshot
Fig. 10 Nuclear Medicine market driver impact
Fig. 11 Global cancer cases projections-2030 (Number of new registered cases)
Fig. 12 Nuclear Medicine market restraint impact
Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 14 Porter’s five forces analysis
Fig. 15 Value chain analysis
Fig. 16 Nuclear Medicine Market: Production of Tc-99 (SPECT radioisotopes)
Fig. 17 Nuclear Medicine market: Production of 18F-FDG (PET radioisotopes)
Fig. 18 Company market share analysis
Fig. 19 Company market position analysis
Fig. 20 Company market position analysis
Fig. 21 Competitive dashboard analysis
Fig. 22 Regional network map
Fig. 23 Nuclear Medicine market: Product outlook and key takeaways
Fig. 24 Nuclear Medicine market: Product movement analysis
Fig. 25 Diagnostic products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 SPECT products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 TC-99m market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 TL-201 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 GA-67 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 I-123 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Other SPECT products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 PET products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 F-18 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 SR-82/RB-82 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Other PET products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Therapeutic products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Alpha emitters market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 RA-223 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Beta emitters market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 I-131 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Y-90 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 SM-153 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Re-186 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Lu-177 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Other beta emitters market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Brachytherapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Cesium-131 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Iodine-125 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Palladium-103 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Iridium-192 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Other brachytherapy products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Nuclear Medicine market: Application outlook and key takeaways
Fig. 53 Nuclear Medicine market: Application movement analysis
Fig. 54 Cardiology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Thyroid market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 Lymphoma market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Bone metastasis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 Endocrine tumor market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Other market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Nuclear Medicine market: End-use outlook and key takeaways
Fig. 63 Nuclear Medicine market: End-use movement analysis
Fig. 64 Hospitals & Clinics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 Diagnostic Centers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Nuclear Medicine market: Regional outlook and key takeaways
Fig. 68 Nuclear Medicine market: Regional movement analysis
Fig. 69 North America SWOT analysis
Fig. 70 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 U.S. key country dynamics
Fig. 72 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 Canada key country dynamics
Fig. 74 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Europe SWOT analysis
Fig. 76 Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 UK key country dynamics
Fig. 78 UK market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Germany key country dynamics
Fig. 80 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 Italy key country dynamics
Fig. 82 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Spain key country dynamics
Fig. 84 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 85 France key country dynamics
Fig. 86 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 Russia key country dynamics
Fig. 88 Russia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 Netherlands key country dynamics
Fig. 88 Netherlands market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 89 Denmark key country dynamics
Fig. 90 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 Sweden key country dynamics
Fig. 92 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 93 Norway key country dynamics
Fig. 94 Norway market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 95 Asia Pacific SWOT analysis
Fig. 96 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 97 Japan key country dynamics
Fig. 98 Japan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 99 China key country dynamics
Fig. 100 China market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 101 India key country dynamics
Fig. 102 India market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 103 Singapore key country dynamics
Fig. 104 Singapore market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 105 Australia key country dynamics
Fig. 106 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 107 South Korea key country dynamics
Fig. 108 8 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 109 Thailand key country dynamics
Fig. 110 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 111 Philippines key country dynamics
Fig. 112 Philippines market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 113 New Zealand key country dynamics
Fig. 114 New Zealand market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 115 Malaysia key country dynamics
Fig. 116 Malaysia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 117 Latin America SWOT analysis
Fig. 118 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 119 Brazil key country dynamics
Fig. 120 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 121 Mexico key country dynamics
Fig. 122 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 123 Argentina key country dynamics
Fig. 124 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 125 Middle East & Africa SWOT analysis
Fig. 126 Middle East and Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 127 South Africa key country dynamics
Fig. 128 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 129 Saudi Arabia key country dynamics
Fig. 130 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 131 UAE key country dynamics
Fig. 132 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 133 Israel key country dynamics
Fig. 134 Israel market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 135 Turkey key country dynamics
Fig. 136 Turkey market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 137 Kuwait key country dynamics
Fig. 138 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 139 Company Market Position Analysis
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Nuclear Medicine market snapshot
Fig. 10 Nuclear Medicine market driver impact
Fig. 11 Global cancer cases projections-2030 (Number of new registered cases)
Fig. 12 Nuclear Medicine market restraint impact
Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 14 Porter’s five forces analysis
Fig. 15 Value chain analysis
Fig. 16 Nuclear Medicine Market: Production of Tc-99 (SPECT radioisotopes)
Fig. 17 Nuclear Medicine market: Production of 18F-FDG (PET radioisotopes)
Fig. 18 Company market share analysis
Fig. 19 Company market position analysis
Fig. 20 Company market position analysis
Fig. 21 Competitive dashboard analysis
Fig. 22 Regional network map
Fig. 23 Nuclear Medicine market: Product outlook and key takeaways
Fig. 24 Nuclear Medicine market: Product movement analysis
Fig. 25 Diagnostic products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 SPECT products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 TC-99m market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 TL-201 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 GA-67 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 I-123 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Other SPECT products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 PET products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 F-18 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 SR-82/RB-82 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Other PET products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Therapeutic products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Alpha emitters market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 RA-223 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Beta emitters market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 I-131 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Y-90 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 SM-153 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Re-186 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Lu-177 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Other beta emitters market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Brachytherapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Cesium-131 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Iodine-125 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Palladium-103 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Iridium-192 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Other brachytherapy products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Nuclear Medicine market: Application outlook and key takeaways
Fig. 53 Nuclear Medicine market: Application movement analysis
Fig. 54 Cardiology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Thyroid market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 Lymphoma market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Bone metastasis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 Endocrine tumor market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Other market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Nuclear Medicine market: End-use outlook and key takeaways
Fig. 63 Nuclear Medicine market: End-use movement analysis
Fig. 64 Hospitals & Clinics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 Diagnostic Centers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Nuclear Medicine market: Regional outlook and key takeaways
Fig. 68 Nuclear Medicine market: Regional movement analysis
Fig. 69 North America SWOT analysis
Fig. 70 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 U.S. key country dynamics
Fig. 72 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 Canada key country dynamics
Fig. 74 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Europe SWOT analysis
Fig. 76 Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 UK key country dynamics
Fig. 78 UK market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Germany key country dynamics
Fig. 80 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 Italy key country dynamics
Fig. 82 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Spain key country dynamics
Fig. 84 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 85 France key country dynamics
Fig. 86 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 Russia key country dynamics
Fig. 88 Russia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 Netherlands key country dynamics
Fig. 88 Netherlands market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 89 Denmark key country dynamics
Fig. 90 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 Sweden key country dynamics
Fig. 92 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 93 Norway key country dynamics
Fig. 94 Norway market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 95 Asia Pacific SWOT analysis
Fig. 96 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 97 Japan key country dynamics
Fig. 98 Japan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 99 China key country dynamics
Fig. 100 China market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 101 India key country dynamics
Fig. 102 India market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 103 Singapore key country dynamics
Fig. 104 Singapore market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 105 Australia key country dynamics
Fig. 106 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 107 South Korea key country dynamics
Fig. 108 8 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 109 Thailand key country dynamics
Fig. 110 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 111 Philippines key country dynamics
Fig. 112 Philippines market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 113 New Zealand key country dynamics
Fig. 114 New Zealand market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 115 Malaysia key country dynamics
Fig. 116 Malaysia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 117 Latin America SWOT analysis
Fig. 118 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 119 Brazil key country dynamics
Fig. 120 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 121 Mexico key country dynamics
Fig. 122 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 123 Argentina key country dynamics
Fig. 124 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 125 Middle East & Africa SWOT analysis
Fig. 126 Middle East and Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 127 South Africa key country dynamics
Fig. 128 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 129 Saudi Arabia key country dynamics
Fig. 130 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 131 UAE key country dynamics
Fig. 132 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 133 Israel key country dynamics
Fig. 134 Israel market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 135 Turkey key country dynamics
Fig. 136 Turkey market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 137 Kuwait key country dynamics
Fig. 138 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 139 Company Market Position Analysis
Companies Mentioned
- ECKERT & ZIEGLER
- MALLINCKRODT
- CURIUM PHARMA
- GENERAL ELECTRIC
- JUBILANT LIFE SCIENCES LTD.
- BRACCO IMAGING S.P.A.
- NORDION (CANADA), INC.
- THE INSTITUTE FOR RADIOELEMENTS (IRE - IRE ELIT - BE)
- AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANIZATION (ANSTO)
- NTP RADIOISOTOPES SOC LTD.
- ECZACIBAŞI-MONROL
- LANTHEUS MEDICAL IMAGING, INC.
- CARDINAL HEALTH
- NOVARTIS AG
- BAYER AG
- POINT BIOPHARMA GLOBAL INC.
- TELIX PHARMACEUTICALS
- ACTINIUM PHARMACEUTICALS, INC
- IBA GROUP
- SIRTEX MEDICAL
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 170 |
| Published | May 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 9.1 Billion |
| Forecasted Market Value ( USD | $ 22.3 Billion |
| Compound Annual Growth Rate | 11.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
